Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Accord Rolls Out Zercepac Trastuzumab Biosimilar In UK

Rival To Herceptin Was Developed By China’s Shanghai Henlius Biotech

Executive Summary

Accord has launched its first monoclonal antibody biosimilar and fourth biosimilar overall, introducing in the UK the Zercepac version of trastuzumab developed by China’s Shanghai Henlius Biotech.

You may also be interested in...



Henlius Gets Australian Nod For Trastuzumab

Shanghai Henlius Biotech has celebrated an Australian approval for its Hanquyou trastuzumab biosimilar rival to Herceptin, which has been approved by the country’s TGA under the names Tuzucip and Trastucip via local partner Cipla.

Prestige And Intas Strike International Bevacizumab Deal

Prestige Biopharma and Intas Pharmaceuticals have announced a commercialization deal for Prestige’s HD204 proposed bevacizumab biosimilar, covering a range of territories including markets in the Americas, Europe, Africa and Asia.

Sandoz EMA Trastuzumab Application Follows US Filing

Sandoz and EirGenix have followed their US filing for a biosimilar rival to Herceptin with a European filing for the EG12014 trastuzumab candidate.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB150287

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel